Kyoto University Innovation Capital

Kyoto University Innovation Capital Co., Ltd. (Kyoto iCAP) is a venture capital firm established in December 2014, wholly owned by the National University Corporation Kyoto University. The firm's core mission is to foster the creation of next-generation industries by investing in and supporting startup companies that commercialize advanced research outcomes from Kyoto University and other national universities. They employ a hands-on approach, assisting with business and development plans to bring academic knowledge and technology to market. Kyoto iCAP is dedicated to identifying and nurturing technology seeds with high social impact, aiming to bridge the gap between cutting-edge research and commercial viability.

The firm was founded with the explicit goal of addressing the challenge faced by Japanese researchers whose groundbreaking work often found commercial application primarily through overseas companies. To counter this, Kyoto iCAP not only seeks out promising investment opportunities but also actively engages in startup support programs. These include the Entrepreneur-in-Residence (EIR-iCAP) program, which enables aspiring entrepreneurs to build businesses based on university research, and the Entrepreneurial Collaboration Program (ECC-iCAP), designed to connect researchers with business professionals to facilitate new venture creation. This strategic focus on both investment and incubation underscores their commitment to cultivating a robust university-led startup ecosystem in Japan.

Kyoto University Innovation Capital invests across a diverse range of deep-tech sectors, including biotechnology, healthcare, life sciences, artificial intelligence, IoT, new materials, clean technology, energy, food, and agriculture. Notable investments in their portfolio include LegalOn Technologies, which focuses on AI-powered legal contract review, ACT Genomics for genomics services in cancer, Kyoto Fusioneering in nuclear fusion reactor technology, and Lisata, a developer of therapeutics for cancer and vascular disorders. The firm's portfolio has also seen successful exits, including IPOs for companies like Chordia Therapeutics and Cuorips, and acquisitions such as Lisata and ACT Genomics.

The team at Kyoto University Innovation Capital comprises professionals with diverse backgrounds spanning finance, pharmaceuticals, chemistry, life sciences, and business development. Led by President and CEO Ko Kusumi, the investment team includes individuals with extensive experience in corporate finance, venture capital, research and development, and startup acceleration. Their collective expertise enables the firm to provide comprehensive support to portfolio companies, from strategic planning and fundraising to market entry and global expansion. The firm also maintains an international presence with a resident manager in Singapore, reflecting its ambition to support the global expansion of university-originated startups.